STATEMENT OF AUTHORITY
AND
CONFIDENTIALITY COMMITMENT FROM
THE HEALTH PRODUCTS REGULATORY AUTHORITY OF IRELAND
NOT TO PUBLICLY DISCLOSE NON-PUBLIC INFORMATION SHARED
BY
THE UNITED STATES FOOD AND DRUG ADMINISTRATION

The United States Food and Drug Administration (FDA), is authorized under 21 C.F.R. § 20.89 to
disclose non-public information to the Health Products Regulatory Authority of Ireland (HPRA)
regarding FDA-regulated products as part of cooperative law enforcement or cooperative
regulatory activities.

The HPRA understands that some of the information it receives from FDA may include non-public
information exempt from public disclosure under the laws and regulations of the United States of
America, which is confidential commercial information; trade secret information; personal privacy
information; law enforcement information; designated national security information; or internal,
pre-decisional information. The HPRA understands that this non-public information is shared in
confidence and that FDA considers it critical that the HPRA maintain the confidentiality of the
information. Public disclosure of this information by the HPRA could seriously jeopardize any
further scientific and regulatory interactions between FDA and the HPRA. FDA will advise the
HPRA of the non-public status of the information at the time that the information is shared.

Therefore, the HPRA certifies that it:

1. has the authority to protect from public disclosure such non-public information provided
to the HPRA in confidence by FDA;

2. will not publicly disclose such FDA-provided non-public information without the written
authorization of the owner of the information, the written authorization from the individual who is
the subject of the personal privacy information, or a written statement from FDA that the
information no longer has non-public status;

3. will inform FDA promptly of any effort made by judicial or legislative mandate to obtain
FDA-provided non-public information from the HPRA. If such judicial or legislative mandate
orders disclosure of FDA-provided non-public information, the HPRA will take all appropriate
legal measures in an effort to ensure that the information will be disclosed in a manner that
protects the information from public disclosure; and
4. will promptly inform FDA of any changes to the laws applicable to the HPRA, or to any relevant policies or procedures, that would affect the HPRA’s ability to honor the commitments in this document.

Signed on behalf of the HPRA:

---/S/---

Pat O’Mahony
Chief Executive
The Health Products Regulatory Authority
Kevin O’Malley House
Earlsfort Centre
Earlsfort Terrace
Dublin 2
Ireland

Telephone: +353 (0)1 676 4971
Facsimile: +353 (0)1 676 7836

2/6/2015